Differential sensitivities of recombinant human topoisomerase IIα and β to various classes of topoisomerase II-interacting agents

Biochemical Pharmacology

Volumn 56, Issue 4, 1998, Pages 503-507

  Perrin, Dominique ^a   Van Hille, Benoît ^a   Hill, Bridget T ^a  

^a INSTITUT DE RECHERCHE PIERRE FABRE   (France)

Author keywords

Antitumour agents; Catalytic activity; DNA decatenation; Topoisomerase II ; Topoisomerase II ; Topoisomerase II interacting agents

Indexed keywords

2,3 BIS(3,5 DIOXO 1 PIPERAZINYL)BUTANE; 2,3 BIS(3,5 DIOXOPIPERAZIN 1 YL)BUTANE; ACLARUBICIN; AMSACRINE; ANTINEOPLASTIC AGENT; BISANTRENE; DACTINOMYCIN; DAUNORUBICIN; DISTAMYCIN A; DNA TOPOISOMERASE; DNA TOPOISOMERASE INHIBITOR; ETOPOFOS; ETOPOSIDE; ETOPOSIDE DERIVATIVE; GL 331; INTOPLICINE; ISOENZYME; MITOXANTRONE; RAZOXANE; SURAMIN; TENIPOSIDE; UNCLASSIFIED DRUG;

ARTICLE; ENZYME ACTIVE SITE; ENZYME BINDING; ENZYME INHIBITION; ENZYME PURIFICATION; HUMAN; IN VITRO STUDY; PRIORITY JOURNAL;

ANTINEOPLASTIC AGENTS; DNA TOPOISOMERASES, TYPE II; ENZYME INHIBITORS; HUMANS; ISOENZYMES; RECOMBINANT PROTEINS;

EID: 0031722207     PISSN: 00062952     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0006-2952(98)00082-3     Document Type: Article

References (22)

1. Roca J. The mechanisms of DNA topoisomerases. TIBS. 20:1995;156-160.
2. Drake F.H., Hoffmann G.A., Bartus H.F., Mattern M.R., Crooke S.T., Mirabelli C.K. Biochemical and pharmacological properties of p170 and p180 forms of topoisomerase II. Biochemistry. 28:1989;8154-8160.
3. Tsai-Pflugfelder M., Liu L.F., Liu A.A., Tewey K.M., Whang-Peng J., Knutsen T., Huebner K., Croce C.M., Wang J.C. Cloning and sequencing of cDNA encoding human DNA topoisomerase II and localization of the gene to chromosome region 17q21-22. Proc Natl Acad Sci USA. 85:1988;7177-7181.
4. Chung T.D.Y., Drake F.H., Tan K.B., Per S.R., Crooke S.T., Mirabelli C.K. Characterization and immunologic detection of cDNA clones encoding two human DNA topoisomerase II isozymes. Proc Natl Acad Sci USA. 86:1989;9431-9435.
5. Jenkins J.R., Ayton P., Jones T., Davies S.L., Simmons D.L., Harris A.L., Sheer D., Hickson I. Isolation of cDNA clones encoding the β isozyme of human DNA topoisomerase II and localisation of the gene to chromosome 3P24. Nucleic Acid Res. 20:1992;5587-5592.
6. Austin C.A., Sng J.H., Patel S., Fischer L.M. Novel HeLa topoisomerase II is the IIβ isoform: Complete coding sequence and homology with other type II topoisomerases. Biochim Biophys Acta. 1172:1993;283-291.
7. Wasserman R.A., Austin C.A., Fisher L.M., Wang J.C. Use of yeast in the study of anticancer drugs targeting DNA topoisomerases: Expression of a functional recombinant human DNA topoisomerase IIα in yeast. Cancer Res. 53:1993;3591-3596.
8. Austin C.A., Marsh K.L., Wasserman R.A., Willmore E., Sayer P.J., Wang J.C., Fischer L.M. Expression, domain structure, and enzymatic properties of an active recombinant human DNA topoisomerase IIβ J Biol Chem. 270:1995;15739-15746.
9. Jensen S., Redwood C.S., Jenkins J.R., Andersen A.H., Hickson I.D. Human DNA topoisomerases α and β can functionally substitute for yeast TOP2 in chromosome segregation and recombination. Mol Gen Genet. 252:1996;79-86.
10. Meczes E.L., Marsh K.L., Fisher L.M., Rogers M.P., Austin C.A. Complementation of temperature-sensitive topoisomerase II mutations in Saccharomyces cerevisiae by a human Top2β construct allows the study of topoisomerase IIβ inhibitors in yeast. Cancer Chemother Pharmacol. 39:1997;367-375.
11. Woessner R.D., Mattern M.R., Mirabelli C.K., Johnson R.K., Drake F.H. Proliferation- and cell-dependent differences in expression of the 170 kDa and 180 kDa forms of topoisomerase II in NIH-3T3 cells. Cell Growth Diff. 2:1991;209-214.
12. Meyer K.N., Kjeldsen E., Straub T., Knudsen B.R., Hickson I.D., Kikuchi A., Kreipe H., Boege F. Cell cycle-coupled relocation of types I and II topoisomerases and modulation of catalytic enzyme activities. J Cell Biol. 136:1997;775-788.
13. Turley H., Comley M., Houlbrook S., Nozaki A., Hickson I.D., Gatter K., Harris A.L. The distribution and expression of the two isoforms of DNA topoisomerase II in normal and neoplastic human tissues. Br J Cancer. 75:1997;1340-1346.
14. Sehested M., Jensen P.B. Mapping of DNA topoisomerase II poisons (etoposide, clerocidin) and catalytic inhibitors (aclarubicin, ICRF-187) to four distinct steps in the topoisomerase II catalytic cycle. Biochem Pharmacol. 51:1996;879-886.
15. Capranico G., Zunino F. Antitumor inhibitors of DNA topoisomerases. Curr Pharm Design. 1:1995;1-14.
16. Cornaroti M., Tinelli S., Willmore E., Zunino F., Fischer L.M., Austin C.A., Capranico G. Drug sensitivity and sequence specificity of human recombinant DNA topoisomerases IIα (p170) and IIβ (p180). Mol Pharmacol. 50:1996;1463-1471.
17. Worland S.T., Wang J.C. Inducible overexpression and active site mapping of DNA topoisomerase II from the yeast Saccharomyces cerevisiae. J Biol Chem. 264:1989;4412-4416.
18. 4. Nature. 227:1970;680-688.
19. Kragh Larsen A., Grondard L., Couprie J., Desoize B., Comoe L., Jardillier J.-C., Riou J.-F. The antileukemic alkaloid fagaronine is an inhibitor of DNA topoisomerases I and II. Biochem Pharmacol. 46:1993;1403-1412.
20. Brown G.A., McPherson J.P., Gu L., Hedley D.W., Toso R., Deuchars K.L., Freedman M.H., Goldenberg G.J. Relationship of DNA topoisomerase IIα and β expression to cytotoxicity of antineoplastic agents in human acute lymphoblastic leukemia cell lines. Cancer Res. 55:1995;78-82.
21. Houlbrook S., Addison C.M., Davies S.L., Carmichael J., Stratford I.J., Harris A.L., Hickson I.D. Relationship between expression of topoisomerase II isoforms and intrinsic sensitivity to topoisomerase II inhibitors in breast cell cancer cell lines. Br J Cancer. 72:1995;1454-1461.
22. 4. Br J Cancer. 74:1996;1869-1876.